浙江海正药业股份有限公司第四次股份回购实施结果暨股份变动公告深度解析
浙江海正药业股份有限公司第四次股份回购实施结果暨股份变动公告深度解析
关键点概述
- 回购方案首次披露于2025年5月13日，回购期限为2025年5月12日至2026年5月11日。
- 回购金额区间为5,000万元至10,000万元，回购价格上限为13元/股。
- 本次回购股份主要用于员工持股计划或股权激励，而非减少公司注册资本或转换可转债。
- 实际回购股份10,194,600股，占公司总股本的0.85%，实际回购金额为98,990,244.98元，实际回购价格区间为8.92元/股至10.69元/股。
回购方案审批与执行情况详细
公司于2025年5月12日召开董事会和监事会，审议通过了第四次以集中竞价交易方式回购股份的议案。回购资金全部来源于自有资金，方案明确回购价格不超过13元/股，期限为12个月。公司已按计划完成回购，实际执行情况与原方案一致。
回购实施情况及影响
- 2025年5月22日公司首次实施回购，2026年3月16日完成回购。
- 回购均价为9.71元/股，资金总额约9899万元（不含交易费用）。
- 回购方案的完成不会对公司正常经营活动、财务状况产生重大影响，也不会导致公司股权分布不符合上市条件或公司控制权发生变化。
相关主体买卖股票情况
在回购期间，公司董事、高级管理人员、控股股东、实际控制人均未买卖公司股票，避免了内幕交易风险。
股份变动及结构调整
回购前后公司股份变动如下（单位：股）：
| 股份类别 |
回购前数量 |
比例(%) |
回购后数量 |
比例(%) |
| 有限售条件流通股份 |
659,250 |
0.05 |
87,000 |
0.01 |
| 无限售条件流通股份 |
1,198,188,946 |
99.95 |
1,198,761,196 |
99.99 |
| 回购专用证券账户 |
30,176,300 |
2.52 |
40,370,900 |
3.37 |
| 股份总数 |
1,198,848,196 |
1,198,848,196 |
公司2021年限制性股票激励计划预留授予部分第三个解除限售期于2026年2月24日达成，共计57.225万股由有限售条件流通股份转为无限售条件流通股份，公司总股本不变。
已回购股份处理安排
回购股份10,194,600股将用于后续员工持股计划。若在36个月内未能全部使用，未使用部分将依据相关法律法规执行。公司将严格按照披露用途履行决策程序和信息披露义务。
对股东及投资者的影响
- 回购股份用于员工激励，利于提升公司管理层及员工积极性，有望增强公司长期发展动力。
- 回购方案按计划完成，表明公司资金状况稳定，经营稳健。
- 回购价格区间低于回购上限，显示公司对市场股价有信心，也可能为股价提供支撑。
- 没有内幕交易发生，增加市场对公司治理的信任。
潜在股价影响
本次回购计划及实施结果，尤其是用于加强员工持股计划，有助于提升公司核心团队凝聚力，并可能对股价产生正面支撑效果。公司回购价格低于上限，显示市场估值合理。回购完成且未影响公司经营和控制权，有望增强投资者信心。
免责声明
本分析仅供参考，所有信息均来自公司公告，投资者需结合自身风险偏好谨慎决策。公司后续股份使用及信息披露仍需关注，股价波动受多重因素影响，本文不构成任何投资建议。
English Version
In-depth Analysis of Zhejiang Hisun Pharmaceutical Co., Ltd. Fourth Share Buyback Implementation Results and Share Change Announcement
Key Highlights
- The buyback plan was first disclosed on May 13, 2025, with a buyback period from May 12, 2025, to May 11, 2026.
- Buyback amount ranged between RMB 50 million and RMB 100 million, with a price cap of RMB 13/share.
- This buyback is mainly for employee stock ownership plans or equity incentives, not for capital reduction or convertible bond conversion.
- Actual buyback: 10,194,600 shares, accounting for 0.85% of total share capital, total buyback amount RMB 98,990,244.98, buyback price range RMB 8.92–10.69/share.
Buyback Approval and Execution Details
The board and supervisory committee approved the fourth buyback plan on May 12, 2025. The buyback was funded by internal resources, with a price cap of RMB 13/share and a 12-month period. The company executed the plan as scheduled, with no deviations.
Buyback Implementation and Impact
- First buyback executed on May 22, 2025; completed on March 16, 2026.
- Average buyback price RMB 9.71/share, total funds about RMB 98.99 million (excluding transaction fees).
- The buyback has no significant impact on the company’s normal operations, financial status, or control structure.
Shareholder & Insider Trading Situation
During the buyback period, no company directors, senior managers, major shareholders, or actual controllers traded company shares, eliminating insider trading risks.
Share Structure Changes
Before and after buyback, share structure is as follows (shares):
| Share Type |
Before Buyback |
Proportion (%) |
After Buyback |
Proportion (%) |
| Restricted Circulating Shares |
659,250 |
0.05 |
87,000 |
0.01 |
| Unrestricted Circulating Shares |
1,198,188,946 |
99.95 |
1,198,761,196 |
99.99 |
| Buyback Designated Account |
30,176,300 |
2.52 |
40,370,900 |
3.37 |
| Total Shares |
1,198,848,196 |
1,198,848,196 |
The 2021 restricted stock incentive plan reserve vested on Feb 24, 2026, with 572,250 shares moving from restricted to unrestricted, total share capital unchanged.
Handling of Repurchased Shares
All 10,194,600 repurchased shares will be used for employee stock ownership plans. If not used within 36 months, unused shares will be handled per regulations. The company will strictly follow disclosed purposes and fulfill decision and disclosure obligations.
Implications for Shareholders and Investors
- Buyback for employee incentives may boost management and staff motivation, supporting long-term company growth.
- Plan execution shows stable finances and sound operations.
- Buyback price below cap suggests confidence in market valuation and may support share price.
- No insider trading; improved governance credibility.
Potential Share Price Impact
The buyback, especially for employee incentives, may positively affect share price by enhancing core team cohesion. Completion without affecting operations or control could strengthen investor confidence.
Disclaimer
This analysis is for informational purposes only, based on company disclosures. Investors should make decisions based on their own risk appetite. Subsequent usage and information disclosure of repurchased shares should be monitored. Share price is influenced by many factors; this article does not constitute investment advice.
View 海正药业 Historical chart here
